<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Universal</title>
	<atom:link href="http://www.tapanray.in/tag/universal/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Covid Vaccine Challenges – Abidance To Defined Health Norms Stays As Lifeguard</title>
		<link>http://www.tapanray.in/covid-vaccine-challenges-abidance-to-defined-health-norms-stays-as-lifeguard/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=covid-vaccine-challenges-abidance-to-defined-health-norms-stays-as-lifeguard</link>
		<comments>http://www.tapanray.in/covid-vaccine-challenges-abidance-to-defined-health-norms-stays-as-lifeguard/#comments</comments>
		<pubDate>Mon, 16 Nov 2020 00:00:08 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Abidance]]></category>
		<category><![CDATA[challenge]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[cold-chain]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[distribution]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[immunization]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[logistics]]></category>
		<category><![CDATA[norms]]></category>
		<category><![CDATA[program]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UIP]]></category>
		<category><![CDATA[Universal]]></category>
		<category><![CDATA[vaccination]]></category>
		<category><![CDATA[Vaccine]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10327</guid>
		<description><![CDATA[There isn’t even a shade of doubt today that Covid-vaccines are coming. However, some critical questions in this area continue to hang in the air, and are expected to remain so for some more time. Thus, every news on the &#8230; <a href="http://www.tapanray.in/covid-vaccine-challenges-abidance-to-defined-health-norms-stays-as-lifeguard/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/covid-vaccine-challenges-abidance-to-defined-health-norms-stays-as-lifeguard/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>NHPS: &#8220;One Nation, One Scheme is Enticing&#8221;, But Will It Work?</title>
		<link>http://www.tapanray.in/nhps-one-nation-one-scheme-is-enticing-but-will-it-work/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=nhps-one-nation-one-scheme-is-enticing-but-will-it-work</link>
		<comments>http://www.tapanray.in/nhps-one-nation-one-scheme-is-enticing-but-will-it-work/#comments</comments>
		<pubDate>Mon, 12 Mar 2018 00:00:13 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Aayog]]></category>
		<category><![CDATA[Ayushman Bharat]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Coverage]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[insurance]]></category>
		<category><![CDATA[Mahatma Jyotiba Phule Jan Aarogya Abhiyan]]></category>
		<category><![CDATA[Modicare]]></category>
		<category><![CDATA[nation]]></category>
		<category><![CDATA[National Health Protection Scheme]]></category>
		<category><![CDATA[NHPS]]></category>
		<category><![CDATA[Niti]]></category>
		<category><![CDATA[one]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[scheme]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[Universal]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8903</guid>
		<description><![CDATA[Yet another slogan: “One nation &#8211; One Universal Health Coverage (UHC)” would indeed be enticing for many, including India. Nevertheless, that’s just a hope. Let’s now try to get a message out of what has been recently happening around this &#8230; <a href="http://www.tapanray.in/nhps-one-nation-one-scheme-is-enticing-but-will-it-work/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/nhps-one-nation-one-scheme-is-enticing-but-will-it-work/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Tipping Point For Robust Healthcare System In India</title>
		<link>http://www.tapanray.in/a-tipping-point-for-robust-healthcare-system-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-tipping-point-for-robust-healthcare-system-in-india</link>
		<comments>http://www.tapanray.in/a-tipping-point-for-robust-healthcare-system-in-india/#comments</comments>
		<pubDate>Sun, 19 Nov 2017 23:32:58 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2017]]></category>
		<category><![CDATA[ABPI]]></category>
		<category><![CDATA[accelerated]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[bottom]]></category>
		<category><![CDATA[down]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HLEG]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[pathway]]></category>
		<category><![CDATA[point]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Robust]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Tipping]]></category>
		<category><![CDATA[top]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[Universal]]></category>
		<category><![CDATA[Up]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8558</guid>
		<description><![CDATA[“Given the popular uptake of universal health coverage reforms elsewhere in Asia, the Feb 4 elections may be a tipping point for health in India. For example, in 2012, Joko Widodo was elected Governor of Jakarta. He launched popular UHC &#8230; <a href="http://www.tapanray.in/a-tipping-point-for-robust-healthcare-system-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-tipping-point-for-robust-healthcare-system-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Price Control And National Health Security</title>
		<link>http://www.tapanray.in/drug-price-control-and-national-health-security/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-price-control-and-national-health-security</link>
		<comments>http://www.tapanray.in/drug-price-control-and-national-health-security/#comments</comments>
		<pubDate>Mon, 25 Sep 2017 00:00:27 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[funded]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[insurance]]></category>
		<category><![CDATA[irrelevant]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[mentality]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[OECD]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulation]]></category>
		<category><![CDATA[Security]]></category>
		<category><![CDATA[silo]]></category>
		<category><![CDATA[State]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[Universal]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8431</guid>
		<description><![CDATA[&#8216;Without Providing Affordable Medicines, There Can&#8217;t be Health Security&#8217;, said the Union Minister of Chemicals and Fertilizers of India, as reported on September 22, 2017. Although, the Minister made this remark while discussing Government price control on cardiac stents in &#8230; <a href="http://www.tapanray.in/drug-price-control-and-national-health-security/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-price-control-and-national-health-security/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Prescriptions in Generic Names Be Made A Must in India?</title>
		<link>http://www.tapanray.in/prescriptions-in-generic-names-be-made-a-must-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=prescriptions-in-generic-names-be-made-a-must-in-india</link>
		<comments>http://www.tapanray.in/prescriptions-in-generic-names-be-made-a-must-in-india/#comments</comments>
		<pubDate>Mon, 24 Apr 2017 00:00:20 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Aaadhar]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Aushadhi]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[branded generics]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[DTAB]]></category>
		<category><![CDATA[framework]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[identification]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[INN]]></category>
		<category><![CDATA[Jan]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[names]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[oop]]></category>
		<category><![CDATA[OTC]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[PMJAY]]></category>
		<category><![CDATA[prescriptions]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[strategies]]></category>
		<category><![CDATA[Surat]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[unique]]></category>
		<category><![CDATA[Universal]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8196</guid>
		<description><![CDATA[Would prescriptions in generic names be made a must in India? Yes, that’s what Prime Minister Modi distinctly hinted at on April 17, 2017, during the inauguration function of a charitable hospital in Surat. To facilitate this process, his government &#8230; <a href="http://www.tapanray.in/prescriptions-in-generic-names-be-made-a-must-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/prescriptions-in-generic-names-be-made-a-must-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>National Health Policy 2017: Some Silver Linings, Some Trepidation</title>
		<link>http://www.tapanray.in/national-health-policy-2017-some-silver-linings-some-trepidation/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=national-health-policy-2017-some-silver-linings-some-trepidation</link>
		<comments>http://www.tapanray.in/national-health-policy-2017-some-silver-linings-some-trepidation/#comments</comments>
		<pubDate>Mon, 27 Mar 2017 00:00:58 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[1983]]></category>
		<category><![CDATA[2002]]></category>
		<category><![CDATA[2017]]></category>
		<category><![CDATA[All]]></category>
		<category><![CDATA[building]]></category>
		<category><![CDATA[Capacity]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[fundamental]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[lining]]></category>
		<category><![CDATA[List]]></category>
		<category><![CDATA[low]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[NHP]]></category>
		<category><![CDATA[point]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[right]]></category>
		<category><![CDATA[silver]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[to-do]]></category>
		<category><![CDATA[trepidation]]></category>
		<category><![CDATA[tweet]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[Universal]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8158</guid>
		<description><![CDATA[In September 2016, the Supreme Court directed the Indian Government to finalize the ‘National Health Policy (NHP)’ guaranteeing ‘assured health services to all’, a draft version of which was already made available to the public on December 30, 2014. In &#8230; <a href="http://www.tapanray.in/national-health-policy-2017-some-silver-linings-some-trepidation/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/national-health-policy-2017-some-silver-linings-some-trepidation/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Leveraging 3D Printing In Pharma, For Cost Containment And Patient-Centricity</title>
		<link>http://www.tapanray.in/leveraging-3d-printing-in-pharma-for-cost-containment-and-patient-centricity/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=leveraging-3d-printing-in-pharma-for-cost-containment-and-patient-centricity</link>
		<comments>http://www.tapanray.in/leveraging-3d-printing-in-pharma-for-cost-containment-and-patient-centricity/#comments</comments>
		<pubDate>Mon, 06 Jun 2016 00:00:55 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[3d]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[changing]]></category>
		<category><![CDATA[containment]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Leveraging]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Patient-Centricity]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[printing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[role]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[Universal]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7662</guid>
		<description><![CDATA[Today, although a number of new and state of the art drugs is regularly being developed, and brought to the market at a reasonably rapid pace, their access to the majority of the global population has still remained a huge &#8230; <a href="http://www.tapanray.in/leveraging-3d-printing-in-pharma-for-cost-containment-and-patient-centricity/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/leveraging-3d-printing-in-pharma-for-cost-containment-and-patient-centricity/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Universal Health Coverage: The Only Alternative To Drug Price Control in India?</title>
		<link>http://www.tapanray.in/universal-health-coverage-the-only-alternative-to-drug-price-control-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=universal-health-coverage-the-only-alternative-to-drug-price-control-in-india</link>
		<comments>http://www.tapanray.in/universal-health-coverage-the-only-alternative-to-drug-price-control-in-india/#comments</comments>
		<pubDate>Mon, 09 Nov 2015 00:00:27 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[1995]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[2015]]></category>
		<category><![CDATA[Boston]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Coverage]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Failure]]></category>
		<category><![CDATA[foolhardy]]></category>
		<category><![CDATA[Globe]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[HLEG]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[NHP]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Right to Health]]></category>
		<category><![CDATA[Supreme Court]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Turing]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[Universal]]></category>
		<category><![CDATA[‘Committee on Oversight & Government Reform’]]></category>
		<category><![CDATA[‘Kaiser Health Tracking Poll’]]></category>
		<category><![CDATA[“National Health Assurance”]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7257</guid>
		<description><![CDATA[Aggressive drug pricing is becoming a burning issue in the healthcare space, across the world. The raging debate continues in India too, fueled by many factors. In this context, it was quite interesting to note, on July 15, 2015, the &#8230; <a href="http://www.tapanray.in/universal-health-coverage-the-only-alternative-to-drug-price-control-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/universal-health-coverage-the-only-alternative-to-drug-price-control-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is Drug Price Control The Key Growth Barrier For Indian Pharma Industry?</title>
		<link>http://www.tapanray.in/is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry</link>
		<comments>http://www.tapanray.in/is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry/#comments</comments>
		<pubDate>Mon, 19 Oct 2015 00:00:14 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[1995]]></category>
		<category><![CDATA[2011]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[AIOCD]]></category>
		<category><![CDATA[AIOCD-AWACS]]></category>
		<category><![CDATA[apex]]></category>
		<category><![CDATA[Atorvastatin]]></category>
		<category><![CDATA[AWACS]]></category>
		<category><![CDATA[barrier]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[consumer]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[corollary]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Crocin Advance]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[driver]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[health care UHC]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[hikes]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[increases]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[IPM]]></category>
		<category><![CDATA[key]]></category>
		<category><![CDATA[Maharashtra]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[Para 19]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[safeguard]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Universal]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7183</guid>
		<description><![CDATA[The corollary of the above headline could well be: “Are drug price hikes the key growth driver for the Indian Pharmaceutical Market (IPM)?” Whenever the first question, as appears in the headline of this article: “Is drug price control a &#8230; <a href="http://www.tapanray.in/is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Unsustainable New Cancer Drug Prices: Resolution Remains A Far Cry</title>
		<link>http://www.tapanray.in/unsustainable-new-cancer-drug-prices-resolution-remains-a-far-cry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=unsustainable-new-cancer-drug-prices-resolution-remains-a-far-cry</link>
		<comments>http://www.tapanray.in/unsustainable-new-cancer-drug-prices-resolution-remains-a-far-cry/#comments</comments>
		<pubDate>Mon, 13 Apr 2015 00:00:04 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[clinic]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Costs]]></category>
		<category><![CDATA[Coverage]]></category>
		<category><![CDATA[Dekkers]]></category>
		<category><![CDATA[DoP. department of pharmaceuticals]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Far Cry]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[health-economics]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[JAMA]]></category>
		<category><![CDATA[Marjin]]></category>
		<category><![CDATA[Mayo]]></category>
		<category><![CDATA[Nexavar]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[NPPP 2012]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Patented Drugs Pricing]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[public health foundation]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[section 3d]]></category>
		<category><![CDATA[Sloan-Kettering]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[Universal]]></category>
		<category><![CDATA[unsustainable]]></category>
		<category><![CDATA[value based pricing]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6530</guid>
		<description><![CDATA[Prices of new drugs for the treatment of life-threatening ailments, such as cancer, are increasingly becoming unsustainable, across the world, and more in India. As articulated by the American Society of Clinical Oncology in 2014, this is primarily due to &#8230; <a href="http://www.tapanray.in/unsustainable-new-cancer-drug-prices-resolution-remains-a-far-cry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/unsustainable-new-cancer-drug-prices-resolution-remains-a-far-cry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
